Acute cutaneous methotrexate toxicity and severe pancytopenia following methotrexate prophylactic chemotherapy for the prevention of post molar gestational trophoblastic neoplasia-a case report

Authors

  • Gio Paulo C. Pineda Quirino Memorial Medical Center
  • Angelica Anne Chua Department of Obstetrics and Gynecology, Quirino Memorial Medical Center, Metro Manila, Philippines

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20243610

Keywords:

Gestational trophoblastic neoplasia, Methotrexate, Chemoprophylaxis, Molar pregnancy, Methotrexate toxicity

Abstract

Gestational Trophoblastic Neoplasia is a type of malignancy that develops from a molar gestation and occurs when trophoblastic activity remains following evacuation. Evacuation of retained products of conception is the cornerstone in the management of molar pregnancies however, a subset of patients is at risk to develop post-molar gestational trophoblastic neoplasia. Chemoprophylaxis has been controversial and varies across the guidelines set by local societies. In the Philippines, methotrexate chemoprophylaxis is acceptable for patients who are at high risk developing post molar gestational trophoblastic neoplasia and when post-evacuation surveillance is doubtful. We present a 35-year-old gravid patient who was diagnosed with a partial molar pregnancy who underwent methotrexate chemoprophylaxis after suction curettage. The patient was a candidate for chemoprophylaxis since her baseline B-HCG level was elevated to 1,270,300 mIU/ml. 0.8 ml of methotrexate was given intramuscularly on alternating deltoids for 5 doses on 5 consecutive days. The patient was sent home stable with no complaints after her fifth dose however 5 days after her discharge, the patient presented in our emergency room due to pruritic skin lesions. There were multiple, well-defined, irregularly shaped erythematous to violaceous plaques with whitish scales, some with areas of erosions on the forehead, neck, back, inframammary area, abdomen, periumbilical region, bilateral upper arms, buttocks and lower extremities. Blood work up also revealed severe pancytopenia. Aggressive hydration, urine alkalinization, leucovorin rescue therapy, administration of granulocyte macrophage colony stimulating factor, and transfusion of blood products were strategies done for the successful management of the case. Although rare, the development of severe pancytopenia following MTX-administration is linked to a high incidence of morbidity and mortality and must be treated with the highest-level of care. Clearance of methotrexate from the bloodstream, folinic acid therapy, and organ treatment are 3 cornerstones in the management of methotrexate toxicity.

Metrics

Metrics Loading ...

References

Qiuyi W. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. The Cochrane Library. 2017;12:7289.

Yuanyuan L. The effect of prophylactic chemotherapy on treatment outcome of post molar gestational trophoblastic neoplasia. BMC. 2023;23(1):12905.

Estrella S, Agnes L. A randomized controlled trial on the efficacy of methotrexate in preventing post molar gestational trophoblastic disease among patients with high-risk complete hydatidiform mole. Philippine J Obst Gynecol. 2015;39(4):22–7.

Tan, Reyalu T, Lynnette R. Chemoprophylaxis in the Prevention of Postmolar Gestational Trophoblastic Neoplasia: A 5-year Review. Philippine J Obst Gynecol. 2018;44(4):6–11.

Hamed KM, Dighriri IM, Baomar AF, Alharthy BT, Alenazi FE, Alali GH, et al. Overview of methotrexate toxicity: a comprehensive literature review. Cureus. 2022;14(9):24-8.

Kanderi T, Gomez JC, Puthenpura MM, Yarlagadda K, Gangireddy M. Pancytopenia as a complication of low-dose methotrexate in a septuagenarian: a rare presentation. Cureus. 2020;12(6):34-7.

Ajmani S, Preet Singh Y, Prasad S, Chowdhury A, Aggarwal A, Lawrence A, et al. Methotrexate‐induced pancytopenia: a case series of 46 patients. Int J Rheum Dis. 2017;20(7):846-51.

Delyon J, Ortonne N, Benayoun E, Moroch J, Wolkenstein P, Sbidian E, et al. Low-dose methotrexate-induced skin toxicity: Keratinocyte dystrophy as a histologic marker. J Am Acad Dermatol. 2015;73(3):484-90.

Bhargava M, Kopp CR, Naidu S, Dhibar DP, Saroch A, Khadwal A, et al. Comparison of two doses of leucovorin in severe low-dose methotrexate toxicity–a randomized controlled trial. Arthr Res Ther. 2023;25(1):82.

Goldfrank's Toxicologic Emergencies. 11e Eds. Lewis S. Nelson, et al. McGraw Hill. 2019.

Downloads

Published

2024-11-28

Issue

Section

Case Reports